Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Taiwanese (TAIEX) Pharma Industry Analysis

UpdatedJun 05, 2026
DataAggregated Company Financials
Companies59
  • 7D1.3%
  • 3M-17.3%
  • 1Y-11.3%
  • YTDn/a

The Pharma is pretty flat in the last 7 days, but Bora Pharmaceuticals has stood out, gaining 8.2%. As for the longer term, the industry has declined 11% in the last year. Earnings are forecast to grow by 92% annually.

Industry Valuation and Performance

Has the Taiwanese Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 05 Jun 2026NT$589.0bNT$123.1bNT$19.0b17.9x31x4.8x
Sun, 03 May 2026NT$621.3bNT$119.4bNT$20.6b14.7x30.1x5.2x
Tue, 31 Mar 2026NT$579.0bNT$119.3bNT$20.8b15x27.8x4.9x
Thu, 26 Feb 2026NT$759.3bNT$119.3bNT$12.4b17x61.2x6.4x
Sat, 24 Jan 2026NT$800.6bNT$119.3bNT$12.4b17.5x64.5x6.7x
Mon, 22 Dec 2025NT$747.3bNT$118.0bNT$12.3b16.7x60.8x6.3x
Wed, 19 Nov 2025NT$676.6bNT$117.4bNT$12.4b16.1x54.7x5.8x
Fri, 17 Oct 2025NT$794.3bNT$118.3bNT$9.6b15.8x82.6x6.7x
Sun, 14 Sep 2025NT$842.2bNT$118.4bNT$10.2b16.5x82.4x7.1x
Tue, 12 Aug 2025NT$690.2bNT$117.5bNT$12.5b17.3x55.4x5.9x
Thu, 10 Jul 2025NT$630.7bNT$116.0bNT$14.3b18.5x44.1x5.4x
Sat, 07 Jun 2025NT$631.0bNT$115.9bNT$14.3b19.1x44.2x5.4x
Mon, 05 May 2025NT$566.9bNT$113.3bNT$10.6b18.9x53.5x5x
Wed, 02 Apr 2025NT$588.8bNT$112.8bNT$10.8b18.3x54.4x5.2x
Fri, 28 Feb 2025NT$674.8bNT$109.4bNT$11.5b23.5x58.7x6.2x
Sun, 26 Jan 2025NT$612.0bNT$109.3bNT$11.4b21.7x53.5x5.6x
Tue, 24 Dec 2024NT$591.2bNT$109.3bNT$11.4b21.7x51.7x5.4x
Thu, 21 Nov 2024NT$632.2bNT$109.1bNT$11.5b23x55.1x5.8x
Sat, 19 Oct 2024NT$622.7bNT$104.7bNT$8.9b27x69.6x5.9x
Mon, 16 Sep 2024NT$630.8bNT$104.7bNT$8.9b25.1x70.5x6x
Wed, 14 Aug 2024NT$640.0bNT$101.4bNT$7.3b28.7x87.3x6.3x
Fri, 12 Jul 2024NT$681.6bNT$100.5bNT$6.8b31.8x99.8x6.8x
Sun, 09 Jun 2024NT$636.7bNT$100.4bNT$7.1b29.7x89.1x6.3x
Tue, 07 May 2024NT$618.1bNT$101.8bNT$9.3b25.1x66.1x6.1x
Thu, 04 Apr 2024NT$696.9bNT$101.5bNT$9.4b26.7x74.5x6.9x
Sat, 02 Mar 2024NT$657.1bNT$101.7bNT$8.3b23.6x79.5x6.5x
Mon, 29 Jan 2024NT$590.5bNT$101.9bNT$7.8b23.7x75.8x5.8x
Wed, 27 Dec 2023NT$576.9bNT$101.6bNT$7.6b23.5x75.6x5.7x
Fri, 24 Nov 2023NT$567.4bNT$101.6bNT$8.3b23.6x68.5x5.6x
Sun, 22 Oct 2023NT$521.7bNT$101.7bNT$9.6b20.2x54.2x5.1x
Tue, 19 Sep 2023NT$564.3bNT$101.7bNT$9.6b22.5x58.6x5.6x
Thu, 17 Aug 2023NT$546.0bNT$101.1bNT$9.1b20.6x60.3x5.4x
Sat, 15 Jul 2023NT$569.2bNT$98.7bNT$10.1b16.9x56.6x5.8x
Mon, 12 Jun 2023NT$588.0bNT$98.6bNT$10.1b17x58.5x6x
Price to Earnings Ratio

58.5x


Total Market Cap: NT$588.0bTotal Earnings: NT$10.1bTotal Revenue: NT$98.6bTotal Market Cap vs Earnings and Revenue0%0%0%
Taiwanese Pharma Industry Price to Earnings3Y Average 62.7x202420252026
Current Industry PE
  • Investors are pessimistic on the Taiwanese Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 30.8x which is lower than its 3-year average PE of 62.7x.
  • The 3-year average PS ratio of 5.9x is higher than the industry's current PS ratio of 4.8x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 24% per year over the last three years.
  • Revenues for these companies have grown 7.7% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Comparison

How does Taiwanese Pharma compare with similar industries?

TW Market4.41%
Healthcare3.96%
Pharma1.27%
Pharma1.27%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
6472 Bora PharmaceuticalsNT$371.507.4%
+NT$3.2b		-46.3%PE28x
1795 Lotus PharmaceuticalNT$198.501.8%
+NT$919.8m		-16.2%PE13.5x
4105 TTY BiopharmNT$75.502.9%
+NT$522.2m		-1.9%PE11.7x
4123 Center LaboratoriesNT$38.801.4%
+NT$410.6m		1.4%PE2.7x
3705 YungShin Global HoldingNT$57.302.7%
+NT$399.5m		-7.0%PE19.3x

Latest News

1789
NT$20.10
ScinoPharm Taiwan
7D
1.8%
1Y
17.2%
1795
NT$198.50
Lotus Pharmaceutical
7D
1.8%
1Y
-16.2%
Narrative Update • May 25

1795: Expanded Respiratory Launch Will Support Higher Future Margins

Analysts have lifted their price target for Lotus Pharmaceutical to NT$500, citing updated assumptions that combine a steady fair value view with a slightly higher discount rate, a lower implied revenue growth rate, a higher projected profit margin, and a reduced future P/E multiple. What's in the News Lotus Pharmaceutical announced the global launch of Nintedanib soft gel capsules in 100mg and 150mg strengths across 30 markets, following approvals from regulators including the US FDA, European authorities, Health Canada and the Taiwan FDA (Key Developments).
6467
NT$122.50
Taho Pharmaceuticals
7D
-3.5%
1Y
106.2%
6919
NT$96.00
Caliway Biopharmaceuticals
7D
-4.5%
1Y
-2.0%
4167
NT$20.65
Savior Lifetec
7D
4.8%
1Y
-3.5%
6472
NT$371.50
Bora Pharmaceuticals
7D
7.4%
1Y
-46.3%
4114
NT$30.70
Synmosa Biopharma
7D
1.8%
1Y
-2.4%
4123
NT$38.80
Center Laboratories
7D
1.4%
1Y
1.4%
7829
NT$40.90
Yoda Pharmaceuticals
7D
-11.4%
1Y
10.5%
6535
NT$115.00
Lumosa Therapeutics
7D
-5.7%
1Y
-34.1%
3705
NT$57.30
YungShin Global Holding
7D
2.7%
1Y
-7.0%
4105
NT$75.50
TTY Biopharm
7D
2.9%
1Y
-1.9%
6586
NT$66.00
CHO Pharma
7D
-2.4%
1Y
64.2%
6634
NT$57.40
Sinew Pharma
7D
-14.3%
1Y
14.8%
6785
NT$119.50
Alar Pharmaceuticals
7D
-2.8%
1Y
-20.6%
7878
NT$269.00
Pharmasaga
7D
-2.7%
1Y
n/a